Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial
Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial
Optimi Health 將成爲 ATMA 旅程中心二期試驗的迷幻藥的唯一供應商
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊